We may be young, but we have a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of over 1,300 professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.

We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.

Idorsia is specialized in the discovery, development, and commercialization of innovative medicines, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified, and balanced portfolio, covering multiple therapeutic areas. Our portfolio comprises 2 marketed products and more than 10 assets in clinical development.

Idorsia is a start-up like no other!